https://www.selleckchem.com/products/gw9662.html
Subcutaneous daratumumab (DARA SC; daratumumab co-formulated with recombinant human hyaluronidase PH2 is administered in ~ 5 min and demonstrates safety and efficacy comparable to intravenous daratumumab, with low infusion-related reaction (IRR) rates in global populations. This open-label, multicenter, phase 1 study is the first evaluation of DARA SC in Japanese patients. Eligible patients had relapsed/refractory multiple myeloma (RRMM; ≥ 2 prior lines of therapy including a proteasome inhibitor and immunomodulatory drug). Patients (N
Like
Comment
Share
